More Drugmakers Pursuing Non-competitive Research Partnerships, Deloitte Says
Drugmakers are increasingly using joint ventures and research consortia to accelerate early stages of drug development and share the burden of cost, according to Deloitte.
From 2005 to 2014 saw more than double the number of new R&D partnerships compared with the previous decade — up from approximately 4,000 to about 9,000 — with 4 percent growth annually, Deloitte said in a new report.
The number of research consortia increased almost 10 times, from 34 in 2005 to 334 in 2014 — while pre-clinical partnerships more than doubled, from 256 to 578.
By 2014, 16 percent of all new R&D partnerships were joint ventures, compared to more traditional, asset-focused measures such as licensing agreements or acquisitions. The main motivations for the collaborations included advancing platform technologies and basic research, and gathering specialized scientific expertise in more cost-effective ways than in-house options.